Lifeward Ltd. Reports Second Quarter 2025 Financial Results
Lifeward Ltd. (NASDAQ: LFWD) reported Q2 2025 financial results, showing mixed performance with revenue of $5.7 million, down 15% year-over-year but up 14% sequentially. The company achieved significant operational milestones, including FDA clearance for ReWalk 7 and record Medicare beneficiary placements.
Key financial metrics include a 43.9% gross margin and reduced quarterly cash burn to $3.9 million. The company reported a net loss of $6.6 million, or $0.58 per share. Lifeward appointed new leadership with Mark Grant as CEO and Almog Adar as CFO, while updating 2025 guidance to $24-26 million in revenue.
Notable achievements include successful transition to in-house manufacturing, expanded U.S. payer base, and positive Medicare rulings establishing ReWalk as "reasonable and necessary" for beneficiaries.
Lifeward Ltd. (NASDAQ: LFWD) ha reso noti i risultati finanziari del Q2 2025: performance contrastate con ricavi per $5.7 million, in calo del 15% su base annua ma in aumento del 14% rispetto al trimestre precedente. L'azienda ha raggiunto importanti traguardi operativi, tra cui la approvazione FDA per ReWalk 7 e un numero record di inserimenti di beneficiari Medicare.
I principali indicatori finanziari includono un margine lordo del 43.9% e una riduzione del burn di cassa trimestrale a $3.9 million. La società ha riportato una perdita netta di $6.6 million, pari a $0.58 per azione. Lifeward ha nominato nuova dirigenza con Mark Grant come CEO e Almog Adar come CFO, aggiornando la guidance 2025 a ricavi compresi tra $24-26 million.
Tra i risultati degni di nota: il passaggio con successo alla produzione interna, l'ampliamento della base di payer negli USA e decisioni favorevoli di Medicare che riconoscono ReWalk come "ragionevole e necessario" per i beneficiari.
Lifeward Ltd. (NASDAQ: LFWD) presentó resultados financieros del Q2 2025 con un desempeño mixto: ingresos de $5.7 million, -15% interanual pero +14% secuencial. La compañía alcanzó hitos operativos relevantes, incluida la autorización de la FDA para ReWalk 7 y un récord de colocaciones de beneficiarios de Medicare.
Métricas clave: margen bruto del 43.9% y reducción del cash burn trimestral a $3.9 million. Reportó una pérdida neta de $6.6 million, o $0.58 por acción. Lifeward nombró nueva dirección con Mark Grant como CEO y Almog Adar como CFO, y actualizó su guía 2025 a ingresos de $24-26 million.
Logros destacados: transición exitosa a fabricación interna, expansión de la base de pagadores en EE. UU. y resoluciones favorables de Medicare que establecen ReWalk como "razonable y necesario" para los beneficiarios.
Lifeward Ltd. (NASDAQ: LFWD)는 2025년 2분기 실적을 발표했습니다. 매출은 $5.7 million으로 전년 동기 대비 15% 감소했지만 전분기 대비 14% 증가하는 등 엇갈린 성과를 보였습니다. 회사는 ReWalk 7에 대한 FDA 승인 획득과 Medicare 수혜자 배치 기록 경신 등 주요 운영 이정표를 달성했습니다.
주요 재무 지표로는 43.9%의 총마진과 분기별 현금 소진액이 $3.9 million으로 축소된 점이 있습니다. 순손실은 $6.6 million(주당 $0.58)으로 보고되었습니다. Lifeward는 Mark Grant를 CEO로, Almog Adar를 CFO로 임명했고 2025년 매출 가이던스를 $24-26 million으로 업데이트했습니다.
주목할 만한 성과로는 자체 제조로의 성공적 전환, 미국 지급자(payer) 기반 확대, 그리고 ReWalk을 수혜자에게 "reasonable and necessary"(합리적이고 필요한)하다고 인정한 Medicare의 긍정적 결정들이 있습니다.
Lifeward Ltd. (NASDAQ: LFWD) a publié ses résultats du T2 2025, affichant une performance contrastée : chiffre d'affaires de $5.7 million, en baisse de 15% en glissement annuel mais en hausse de 14% séquentiellement. La société a franchi des étapes opérationnelles majeures, notamment la validation FDA de ReWalk 7 et un record de placements de bénéficiaires Medicare.
Indicateurs clés : marge brute de 43.9% et réduction du cash burn trimestriel à $3.9 million. La perte nette s'élève à $6.6 million, soit $0.58 par action. Lifeward a nommé une nouvelle direction avec Mark Grant comme CEO et Almog Adar comme CFO, et a révisé ses prévisions 2025 à des revenus de $24-26 million.
Parmi les réalisations notables : la transition réussie vers la fabrication interne, l'élargissement du réseau de payeurs aux États-Unis et des décisions favorables de Medicare reconnaissant ReWalk comme "raisonnable et nécessaire" pour les bénéficiaires.
Lifeward Ltd. (NASDAQ: LFWD) veröffentlichte die Finanzergebnisse für Q2 2025 mit gemischter Entwicklung: Umsatz von $5.7 million, minus 15% gegenüber dem Vorjahr, aber plus 14% sequenziell. Das Unternehmen erzielte wichtige operative Meilensteine, darunter die FDA-Freigabe für ReWalk 7 und eine Rekordzahl an Medicare-Platzierungen.
Wesentliche Kennzahlen: Bruttomarge 43.9% und gesenkter Quartals-Cashburn auf $3.9 million. Es wurde ein Nettoverlust von $6.6 million ausgewiesen, bzw. $0.58 je Aktie. Lifeward ernannte neue Führungskräfte: Mark Grant als CEO und Almog Adar als CFO, und passte die 2025-Prognose auf Umsätze von $24–26 million an.
Bemerkenswerte Erfolge sind der erfolgreiche Übergang zur eigenen Fertigung, die Ausweitung der US-Payer-Basis und positive Medicare-Entscheidungen, die ReWalk für Begünstigte als "angemessen und notwendig" einstufen.
- Record number of ReWalk systems placed for Medicare beneficiaries
- FDA clearance and successful launch of ReWalk 7 with over 20 units installed
- Improved quarterly cash burn to $3.9M from $5.6M year-over-year
- Successful transition to in-house manufacturing delivering cost savings
- Positive Medicare ruling establishing ReWalk as 'reasonable and necessary'
- Pipeline growth with over 130 qualified leads in process
- 14% sequential revenue growth from Q1 2025
- Revenue declined 15% year-over-year to $5.7M
- Net loss increased to $6.6M from $4.3M year-over-year
- $2.8M goodwill impairment charge due to significant share price decline
- Traditional products revenue down 19% compared to prior year
- AlterG products revenue decreased 11% year-over-year
- Cash position reduced to $5.1M with no debt
Insights
Lifeward shows mixed Q2 results with revenue decline but improved operational efficiency amid strategic leadership changes.
Lifeward's Q2 results reveal a company in transition, with revenue declining 15% year-over-year to
The
Most encouraging is the significant improvement in cash burn, which decreased to
The
With
The appointment of new CEO Mark Grant and CFO Almog Adar signals a significant strategic shift, likely aimed at accelerating growth and improving financial performance. Their success will depend on expanding ReWalk adoption through the growing qualified pipeline of over 130 leads while maintaining the improved operational efficiency demonstrated this quarter.
Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established
Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process
Appoints new CEO and CFO to spearhead strategic change and accelerate growth
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025.
Recent Highlights and Accomplishments for Lifeward
- Achieved FDA clearance and subsequent U.S. launch in April 2025 for the ReWalk 7, the latest innovation in the ReWalk pipeline, with over 20 ReWalk 7 units installed to date with overwhelmingly positive feedback from customers.
- Expanded and advanced the pipeline of qualified leads for the ReWalk and achieved the highest quarterly total of ReWalk units placed for Medicare beneficiaries since fee schedule established in April 2024.
- Continued expansion of U.S. payer base for the ReWalk Personal Exoskeleton. On the Medicare front, a ruling by an Administrative Law Judge established a legal basis for medical necessity by affirming that the ReWalk Personal Exoskeleton is “reasonable and necessary” for a Medicare beneficiary. Additionally, the partnership with CorLife, a division of NuMotion, has already facilitated and accelerated processing for workers compensation claims, with the first paid claim.
- Improved quarterly cash burn to
$3.9 million , down from$5.6 million in Q2 2024 and$5.5 million in Q1 2025, driven by operational efficiencies, facility consolidations, and other cost reduction initiatives. - Successfully transitioned to in-house manufacturing of the ReWalk Personal Exoskeleton during Q2, concluding the Company’s agreement with Sanmina and delivering cost savings, improved quality control, and greater production flexibility.
- Strengthened the Company’s executive leadership with the appointment of Mark Grant as Lifeward’s President and CEO and Almog Adar as Lifeward’s CFO to bolster the Company’s strategic initiatives toward sustainable growth.
“During the second quarter of 2025, we advanced on multiple fronts; improving cash burn through disciplined cost control, securing regulatory and legal milestones that expand market access, strengthening our manufacturing capabilities, and broadening our global reach through strategic partnerships,” said Mark Grant, President and Chief Executive Officer. “These achievements position Lifeward for greater efficiency, scale, and impact in delivering innovative mobility solutions worldwide.”
Second Quarter 2025 Financial Results
Revenue was
Gross margin was
Total operating expenses in the second quarter of 2025 were
Operating loss in the second quarter of 2025 was
Net loss was
Liquidity
As of June 30, 2025, Lifeward had
2025 Financial Guidance
Lifeward is resetting its full-year 2025 guidance under the new management team, focusing on execution toward revenue of
Conference Call
Lifeward management will host its conference call as follows:
| Date | August 14, 2025 | |
| Time | 8:30 AM EST | |
| Telephone | U.S: | 1-833-316-0561 |
|
| International: | 1-412-317-0690 |
|
| Israel: | 1-80-9212373 |
| Germany: | 0800-6647650 | |
| Access code | Please reference the “Lifeward Earnings Call” | |
| Webcast (live, listen-only and archive) | ||
The archived webcast will be available via the following https://edge.media-server.com/mmc/p/kegov6it or through the “Investors” section on our website at GoLifeward.com.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the ReStore Exo-Suit, and the MyoCycle FES System.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®,ReWalk®, ReStore®,and Alter G® are registered trademarks of Lifeward Ltd.and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.
Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense and acquisition costs allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in Lifeward’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue for the foreseeable future, to be a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees.
The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Lifeward urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.
Lifeward does not provide GAAP reconciliation of its non-GAAP financial guidance because the Company is unable to predict with reasonable certainty and without unreasonable effort items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition-related expense, and earnout expense. The timing and amounts of these items are uncertain and could be material to Lifeward’s results computed in accordance with GAAP.
Lifeward Media Relations:
Kathleen O’Donnell
Vice President, Marketing & New Business Development
Lifeward Ltd.
E: media@golifeward.com
Lifeward Investor Contact:
Almog Adar
Chief Financial Officer
Lifeward Ltd.
E: ir@golifeward.com
| Lifeward Ltd. And subsidiaries | ||||||||||||||||||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Revenue | $ | 5,724 | $ | 6,707 | $ | 10,758 | $ | 11,990 | ||||||||||||||||||||||||
| Cost of revenues | 3,213 | 3,950 | 6,125 | 7,838 | ||||||||||||||||||||||||||||
| Gross profit | 2,511 | 2,757 | 4,633 | 4,152 | ||||||||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||
| Research and development, net | 767 | 1,205 | 1,685 | 2,496 | ||||||||||||||||||||||||||||
| Sales and marketing | 3,785 | 4,403 | 7,622 | 9,417 | ||||||||||||||||||||||||||||
| General and administrative | 1,739 | 1,592 | 3,959 | 3,184 | ||||||||||||||||||||||||||||
| Impairment charges | 2,783 | - | 2,783 | - | ||||||||||||||||||||||||||||
| Total operating expenses | 9,074 | 7,200 | 16,049 | 15,097 | ||||||||||||||||||||||||||||
| Operating loss | (6,563 | ) | (4,443 | ) | (11,416 | ) | (10,945 | ) | ||||||||||||||||||||||||
| Financial income, net | 1 | 144 | 31 | 376 | ||||||||||||||||||||||||||||
| Loss before income taxes | (6,562 | ) | (4,299 | ) | (11,385 | ) | (10,569 | ) | ||||||||||||||||||||||||
| Taxes on income | - | 5 | 11 | 11 | ||||||||||||||||||||||||||||
| Net loss | $ | (6,562 | ) | $ | (4,304 | ) | $ | (11,396 | ) | $ | (10,580 | ) | ||||||||||||||||||||
| Basic net loss per ordinary share | $ | (0.58 | ) | $ | (0.50 | ) | $ | (1.05 | ) | $ | (1.23 | ) | ||||||||||||||||||||
| Weighted average number of shares used in computing net loss per ordinary share basic and diluted | 11,229,427 | 8,608,937 | 10,858,580 | 8,599,520 | ||||||||||||||||||||||||||||
| Lifeward Ltd. And subsidiaries | ||||||||||||||||||||||||||||||||
| Condensed Consolidated Balance Sheets | ||||||||||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||||||||||
| (Unaudited) | (Audited) | |||||||||||||||||||||||||||||||
| June 30, | December 31, | |||||||||||||||||||||||||||||||
| 2025 | 2024 | |||||||||||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 5,139 | $ | 6,746 | ||||||||||||||||||||||||||||
| Restricted Cash | 214 | 197 | ||||||||||||||||||||||||||||||
| Trade receivables, net of credit losses of | 5,864 | 6,004 | ||||||||||||||||||||||||||||||
| Prepaid expenses and other current assets | 1,871 | 1,624 | ||||||||||||||||||||||||||||||
| Inventories | 7,622 | 6,723 | ||||||||||||||||||||||||||||||
| Total current assets | 20,710 | 21,294 | ||||||||||||||||||||||||||||||
| Restricted cash and other long term assets | 228 | 240 | ||||||||||||||||||||||||||||||
| Operating lease right-of-use assets | 354 | 548 | ||||||||||||||||||||||||||||||
| Property and equipment, net | 730 | 867 | ||||||||||||||||||||||||||||||
| Goodwill | 4,755 | 7,538 | ||||||||||||||||||||||||||||||
| Total assets | $ | 26,777 | $ | 30,487 | ||||||||||||||||||||||||||||
| Liabilities and equity | ||||||||||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||||||||||
| Trade payables | 6,113 | 5,022 | ||||||||||||||||||||||||||||||
| Current maturities of operating leases | 296 | 858 | ||||||||||||||||||||||||||||||
| Other current liabilities | 3,951 | 3,737 | ||||||||||||||||||||||||||||||
| Earnout liability | - | 608 | ||||||||||||||||||||||||||||||
| Total current liabilities | 10,360 | 10,225 | ||||||||||||||||||||||||||||||
| Non-current operating leases | 79 | 22 | ||||||||||||||||||||||||||||||
| Other long-term liabilities | 1,228 | 1,391 | ||||||||||||||||||||||||||||||
| Shareholders’ equity | 15,110 | 18,849 | ||||||||||||||||||||||||||||||
| Total liabilities and equity | $ | 26,777 | $ | 30,487 | ||||||||||||||||||||||||||||
| Lifeward Ltd. And subsidiaries | ||||||||||||||||||||||||||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||||||||||
| Six Months Ended | ||||||||||||||||||||||||||||||||
| June 30, | ||||||||||||||||||||||||||||||||
| 2025 | 2024 | |||||||||||||||||||||||||||||||
| Net cash used in operating activities | $ | (9,429 | ) | $ | (13,290 | ) | ||||||||||||||||||||||||||
| Net cash used in investing activities | (5 | ) | - | |||||||||||||||||||||||||||||
| Net cash provided by financing activities | 7,779 | - | ||||||||||||||||||||||||||||||
| Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash | 70 | (15 | ) | |||||||||||||||||||||||||||||
| Decrease in cash, cash equivalents, and restricted cash | (1,585 | ) | (13,305 | ) | ||||||||||||||||||||||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 7,108 | 28,792 | ||||||||||||||||||||||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 5,523 | $ | 15,487 | ||||||||||||||||||||||||||||
| Lifeward Ltd. And subsidiaries | ||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||
| (In thousand) | ||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Revenues based on customer’s location: | ||||||||||||||||||||||||||||||||
| United States | 3,062 | 3,849 | 6,271 | 7,596 | ||||||||||||||||||||||||||||
| Europe | 2,103 | 2,308 | 3,439 | 3,477 | ||||||||||||||||||||||||||||
| Asia - Pacific | 124 | 214 | 166 | 394 | ||||||||||||||||||||||||||||
| Rest of the world | 435 | 336 | 882 | 523 | ||||||||||||||||||||||||||||
| Total Revenues | $ | 5,724 | $ | 6,707 | $ | 10,758 | $ | 11,990 | ||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||||||||
| Dollars in thousands, except per share data | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||||||||
| GAAP net loss | $ | (6,562 | ) | $ | (4,304 | ) | $ | (11,396 | ) | $ | (10,580 | ) | ||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||
| Amortization of intangible assets | - | 832 | - | 1,663 | ||||||||||||||||||||||||||||
| M&A transaction | - | - | - | (467 | ) | |||||||||||||||||||||||||||
| Integration/Rebranding costs | - | - | - | 236 | ||||||||||||||||||||||||||||
| Restructuring | 700 | - | 700 | - | ||||||||||||||||||||||||||||
| Remeasurement of earnout liability | (608 | ) | (488 | ) | (608 | ) | (492 | ) | ||||||||||||||||||||||||
| Impairment charges | 2,783 | - | 2,783 | - | ||||||||||||||||||||||||||||
| Stock-based compensation expenses | 182 | 376 | 402 | 757 | ||||||||||||||||||||||||||||
| Non-GAAP net loss | $ | (3,505 | ) | $ | (3,584 | ) | $ | (8,119 | ) | $ | (8,883 | ) | ||||||||||||||||||||
| Shares used in net loss per share | 11,229,427 | 8,608,937 | 10,858,580 | 8,599,520 | ||||||||||||||||||||||||||||
| Non-GAAP net loss per share | $ | (0.31 | ) | $ | (0.42 | ) | $ | (0.75 | ) | $ | (1.03 | ) | ||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||||||||||||||||||
| GAAP operating loss | $ | (6,563 | ) | (114.7) | % | $ | (4,443 | ) | (66.2) | % | $ | (11,416 | ) | (106.1) | % | $ | (10,945 | ) | (91.3) | % | ||||||||||||
| Amortization of intangible assets | - | - | 832 | 12.4 | % | - | - | 1,663 | 13.9 | % | ||||||||||||||||||||||
| M&A transaction | - | - | - | - | - | - | (467 | ) | (3.9) | % | ||||||||||||||||||||||
| Integration/Rebranding costs | - | - | - | - | - | - | 236 | 2.0 | % | |||||||||||||||||||||||
| Restructuring | 700 | 12.2 | % | - | - | 700 | 6.5 | % | - | - | ||||||||||||||||||||||
| Remeasurement of earnout liability | (608 | ) | (10.6) | % | (488 | ) | (7.3) | % | (608 | ) | (5.7) | % | (492 | ) | (4.1) | % | ||||||||||||||||
| Impairment charges | 2,783 | 48.6 | % | - | - | 2,783 | 25.9 | % | - | - | ||||||||||||||||||||||
| Stock-based compensation expenses | 182 | 3.2 | % | 376 | 5.6 | % | 402 | 3.7 | % | 757 | 6.3 | % | ||||||||||||||||||||
| Non-GAAP operating loss | $ | (3,506 | ) | (61.3) | % | $ | (3,723 | ) | (55.5) | % | $ | (8,139 | ) | (75.7) | % | $ | (9,248 | ) | (77.1) | % | ||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||||||||||||||||||
| GAAP gross profit | $ | 2,511 | 43.9 | % | $ | 2,757 | 41.1 | % | $ | 4,633 | 43.1 | % | $ | 4,152 | 34.6 | % | ||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||
| Amortization of intangible assets | - | - | 383 | 5.7 | % | - | - | 766 | 6.4 | % | ||||||||||||||||||||||
| Stock-based compensation expenses | 4 | 0.1 | % | 5 | 0.1 | % | 7 | 0.1 | % | 9 | 0.1 | % | ||||||||||||||||||||
| Non-GAAP gross profit | $ | 2,515 | 44.0 | % | $ | 3,145 | 46.9 | % | $ | 4,640 | 43.2 | % | $ | 4,927 | 41.1 | % | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||||||||||||||||||
| GAAP research & development | $ | 767 | 13.4 | % | $ | 1,205 | 18.0 | % | $ | 1,685 | 15.7 | % | $ | 2,496 | 20.8 | % | ||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||
| Stock-based compensation expenses | (37) | (0.6) | % | (46) | (0.7) | % | (73) | (0.7) | % | (92 | ) | (0.8) | % | |||||||||||||||||||
| Non-GAAP research & development | $ | 730 | 12.8 | % | $ | 1,159 | 17.3 | % | $ | 1,612 | 15.0 | % | $ | 2,404 | 20.0 | % | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||||||||||||||||||
| GAAP sales & marketing | $ | 3,785 | 66.1 | % | $ | 4,403 | 65.6 | % | $ | 7,622 | 70.8 | % | $ | 9,417 | 78.5 | % | ||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||
| Amortization of intangible assets | - | - | (383 | ) | (5.7) | % | - | - | (765 | ) | (6.4) | % | ||||||||||||||||||||
| Integration/Rebranding costs | - | - | - | - | - | - | (193 | ) | (1.6) | % | ||||||||||||||||||||||
| Restructuring | (277 | ) | (4.8 | )% | - | - | (277 | ) | (2.6) | % | - | - | ||||||||||||||||||||
| Stock-based compensation expenses | (56 | ) | (1.0 | )% | (107 | ) | (1.6) | % | (138 | ) | (1.3) | % | (218 | ) | (1.8) | % | ||||||||||||||||
| Non-GAAP sales & marketing | $ | 3,452 | 60.3 | % | $ | 3,913 | 58.3 | % | $ | 7,207 | 66.9 | % | $ | 8,241 | 68.7 | % | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||||||||||||||||||
| GAAP general & administrative | $ | 1,739 | 30.4 | % | $ | 1,592 | 23.7 | % | $ | 3,959 | 36.8 | % | $ | 3,184 | 26.6 | % | ||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||
| M&A transaction | - | - | - | - | - | - | 467 | 3.9 | % | |||||||||||||||||||||||
| Amortization of intangible assets | - | - | (66 | ) | (1.0) | % | - | - | (132 | ) | (1.1) | % | ||||||||||||||||||||
| Integration/Rebranding costs | - | - | - | - | - | - | (43 | ) | (0.4) | % | ||||||||||||||||||||||
| Restructuring | (423 | ) | (7.4) | % | - | - | (423 | ) | (3.9) | % | - | - | ||||||||||||||||||||
| Remeasurement of earnout liability | 608 | 10.6 | % | 488 | 7.3 | % | 608 | 5.7 | % | 492 | 4.1 | % | ||||||||||||||||||||
| Stock-based compensation expenses | (85 | ) | (1.5) | % | (218 | ) | (3.3) | % | (184 | ) | (1.7) | % | (438 | ) | (3.7) | % | ||||||||||||||||
| Non-GAAP general & administrative | $ | 1,839 | 32.1 | % | $ | 1,796 | 26.7 | % | $ | 3,960 | 36.9 | % | $ | 3,530 | 29.4 | % | ||||||||||||||||
FAQ
What were Lifeward's (LFWD) key financial results for Q2 2025?
Who are the new executives appointed at Lifeward (LFWD)?
What is Lifeward's (LFWD) revenue guidance for 2025?
What progress has Lifeward (LFWD) made with Medicare coverage for ReWalk?
What operational improvements did Lifeward (LFWD) achieve in Q2 2025?
